Loading
Loading
Selective GHRP · Ghrelin receptor agonist · Clean GH release
Highly selective ghrelin-receptor agonist (GHS-R1a) that triggers pulsatile GH release without significantly raising cortisol, prolactin, or ACTH. Considered one of the cleanest GHRP molecules due to its selectivity.
Ipamorelin is a synthetic peptide that has been widely investigated in preclinical research for its selective interaction with growth hormone–related signaling pathways. Classified as a growth hormone secretagogue, Ipamorelin is designed to mimic the activity of endogenous ligands that bind to specific receptors involved in endocrine regulation. Structurally, it is a short chain of amino acids engineered to interact with the growth hormone secretagogue receptor (GHS-R), making it a point of interest in controlled experimental models focused on hormonal modulation.
Across laboratory and animal-based studies, Ipamorelin has been examined for its potential role in stimulating growth hormone release without significantly influencing other hormonal pathways. Researchers often explore how it interacts with receptor-mediated signaling mechanisms, particularly within the hypothalamic-pituitary axis. Compared to earlier compounds in the same class, Ipamorelin has been studied for its relative selectivity, which may allow for more targeted investigation of growth hormone dynamics and downstream metabolic processes.
In experimental settings, Ipamorelin has also been evaluated for its possible influence on physiological processes associated with growth hormone activity, including tissue repair, metabolic regulation, and cellular signaling. Studies frequently assess how it may affect feedback loops, receptor sensitivity, and endocrine balance under controlled conditions, offering insights into broader hormone-related mechanisms.
To support consistency in research, Ipamorelin is synthesized under laboratory conditions to ensure stability and reproducibility across studies. All findings referenced are derived exclusively from non-clinical research. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, ipamorelin peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Ipamorelin Peptide research is most relevant to protocols examining:
GH optimisation research with minimal cortisol/prolactin side effects
Sleep quality and deep-sleep architecture studies
Anti-ageing protocols where hormonal selectivity is a priority
Researchers comparing selective vs non-selective GHRPs
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~2 hours). Review data, confirm baseline recovery before any repeat protocol.
Highly selective ghrelin-receptor agonist (GHS-R1a) that triggers pulsatile GH release without significantly raising cortisol, prolactin, or ACTH. Considered one of the cleanest GHRP molecules due to its selectivity.
| Parameter | Value |
|---|---|
| Dose range | 100–300 mcg/dose |
| Schedule | 1–3× daily (typically at night) |
| Route | Subcutaneous |
| Half-life | ~2 hours |
Dosing too close to or after meals
Fix: GH release is blunted by elevated insulin; dose fasted or 90 min post-meal
Not pairing with CJC-1295 (GHRH)
Fix: synergistic release is substantially greater than either compound alone
Running continuously without breaks
Fix: tachyphylaxis reported with uninterrupted daily use
Expecting dramatic appetite spikes (ipamorelin doesn't significantly raise ghrelin-mediated hunger
Fix: if it does, question the product)
Community & Anecdotal Signal
Community signal is generally positive but methodologically murky. Ipamorelin is almost universally discussed in combination with CJC-1295 rather than as a standalone compound, making isolated attribution nearly impossible. The CJC/Ipa stack is one of the most commonly referenced peptide combinations in biohacking forums. Sleep quality, recovery, and mild body composition changes are the most frequently cited benefits. Side effect reports are notably rare compared to other GH secretagogues, which the community attributes to its GH-specific mechanism without cortisol or prolactin elevation. Dos
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
